

Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

SECTION 1: IDENTIFICATION

Product name : Dexamethasone (0.28%) Formulation

Other means of identification : Dexadreson (A001421)

DEXADRESON INJECTION (52298)

Manufacturer or supplier's details

Company : Intervet Australia Pty Limited (trading as MSD Animal Health)

Address : 91-105 Harpin Street

Bendigo 3550, Victoria Austrailia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Benzyl alcohol	100-51-6	< 10
Dexamethasone	50-02-2	< 0.3

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-



Dexamethasone (0.28%) Formulation

Date of last issue: 14.12.2023 Version Revision Date: SDS Number: 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

None known.

Rinse mouth thoroughly with water.

Most important symptoms

delayed

and effects, both acute and

Protection of first-aiders First Aid responders should pay attention to self-protection,

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Hazardous combustion prod-Carbon oxides

ucts

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

Exposure to combustion products may be a hazard to health.

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe vapours or spray mist.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis	
		(Form of	ters / Permissible		
		exposure)	concentration		
Dexamethasone	50-02-2	TWA	10 μg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	100 μg/100 cm ²	Internal	

Engineering measures: Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Hand protection

Combined particulates and organic vapour type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

Colour : clear

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.



Dexamethasone (0.28%) Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.12.2023

 1.9
 06.04.2024
 5492911-00010
 Date of first issue: 10.03.2020

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Components:

Benzyl alcohol:

Acute oral toxicity : LD50 (Rat): 1,620 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 4.178 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Dexamethasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 6,500 mg/kg



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023
1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

Acute toxicity (other routes of : LD50 (Rat): 14 mg/kg

administration) Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

Benzyl alcohol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Dexamethasone:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Benzyl alcohol:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Method : OECD Test Guideline 405

Dexamethasone:

Species : Rabbit

Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Benzyl alcohol:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

Components:

Benzyl alcohol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Dexamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro assay

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Benzyl alcohol:

Species : Mouse
Application Route : Ingestion
Exposure time : 103 weeks

Method : OECD Test Guideline 451

Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Benzyl alcohol:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Ingestion

Result: negative

Dexamethasone:

Effects on foetal develop-

ment

Test Type: Development

Species: Mouse

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 6 mg/kg body weight Result: Specific developmental abnormalities, Cleft palate

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: NOAEL: 0.025 mg/kg body weight

Result: Specific developmental abnormalities

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: LOAEL: >= 0.062 mg/kg body weight

Result: Specific developmental abnormalities

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: >= 0.02 mg/kg body weight

Result: Skeletal and visceral variations, Retardations

Reproductive toxicity - As-

sessment

May damage the unborn child.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Dexamethasone:

Exposure routes : Oral

Target Organs : Adrenal gland, Immune system, thymus gland

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Benzyl alcohol:



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

Species : Rat NOAEL : 1.072 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 28 Days

Method : OECD Test Guideline 412

Dexamethasone:

Species : Rat

NOAEL : 0.0015 mg/kg

Application Route : Oral Exposure time : 7 d Target Organs : Liver

Remarks : Significant toxicity observed in testing

Species : Rat

LOAEL : 0.003 mg/kg

Application Route : Oral Exposure time : 90 d

Target Organs : Blood, Adrenal gland, thymus gland Remarks : Significant toxicity observed in testing

Species : Rat

LOAEL : 0.125 mg/kg

Application Route : Oral
Exposure time : 6 Weeks
Target Organs : Adrenal gland

Remarks : Significant toxicity observed in testing

Species : Rat
LOAEL : 0.4 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Immune system

Remarks : Significant toxicity observed in testing

Species : Dog
LOAEL : 8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Immune system

Remarks : Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Dexamethasone:

Ingestion : Target Organs: Immune system

Target Organs: Adrenal gland



Dexamethasone (0.28%) Formulation

Version SDS Number: Date of last issue: 14.12.2023 **Revision Date:** 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

Target Organs: Bone

Symptoms: muscle weakness

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Benzyl alcohol:

Toxicity to fish LC50 (Pimephales promelas (fathead minnow)): 460 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 230 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 770

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 310

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 51 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Dexamethasone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 56 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.2

ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.033 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to microorganisms EC50: > 1,000 mg/l



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

Components:

Benzyl alcohol:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 92 - 96 %

Exposure time: 14 d

Dexamethasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 3.54 d

Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Benzyl alcohol:

Partition coefficient: n-

octanol/water

log Pow: 1.05

Dexamethasone:

Partition coefficient: n-

octanol/water

log Pow: 1.83

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen- : Not applicable

ger aircraft)

IMDG-Code

UN number Not applicable Not applicable Proper shipping name Not applicable Class Not applicable Subsidiary risk Not applicable Packing group Not applicable Labels **EmS Code** Not applicable Marine pollutant Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

ADG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable



Dexamethasone (0.28%) Formulation

Date of last issue: 14.12.2023 Version Revision Date: SDS Number: 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Therapeutic Goods (Poisons : Schedule 4

Standard) Instrument

Prohibition/Licensing Requirements

There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regula-

The components of this product are reported in the following inventories:

AICS not determined

DSL not determined

IECSC not determined

SECTION 16: ANY OTHER RELEVANT INFORMATION

Further information

Revision Date 06.04.2024

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Date format dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships;



Dexamethasone (0.28%) Formulation

Version Revision Date: SDS Number: Date of last issue: 14.12.2023 1.9 06.04.2024 5492911-00010 Date of first issue: 10.03.2020

n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN